ArticleIndian journal of gastroenterology : official journal of the Indian Society of Gastroenterology2026
Comparative effectiveness of mirikizumab and risankizumab in patients with ulcerative colitis: A propensity-matched cohort study.
Article in Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesMirikizumab and risankizumab are both anti-IL23 therapies approved for moderate-to-severe ulcerative colitis (UC); however, there is no comparative data to guide their clinical use.
methodsWe performed an exploratory retrospective cohort study in the TriNetX Research Network in adult patients with UC who initiated mirikizumab or risankizumab. The primary outcome was hazard of oral and/or IV corticosteroid use within 180 days. The secondary outcomes were therapy change, colectomy and fecal calprotectin (FCP) response, defined as either a level < 200 µg/g or a decline of > 50%. 1:1 propensity score matching (PSM) was performed for demographics, comorbid conditions, laboratory values and prior UC medications. Risk was expressed as adjusted hazard ratio with 95% confidence intervals (CI).
resultsThere were 98 patients in the mirikizumab cohort (mean age 43.6 ± 18, 58.1% male, 80% White, 72.1% bio-exposed) and 147 patients in the risankizumab cohort (mean age 45.8 ± 17.5, 57.1% male, 80% White, 65.3% bio-exposed). Ustekinumab exposure was similar between the two cohorts (28.5% vs. 22.4%, p = 0.28). After PSM (n = 72); there was a lower incidence of corticosteroid use in the mirikizumab cohort compared to risankizumab cohort (31.9% vs. 44.4%, aHR 0.56, 95% CI 0.32-0.96, log rank p = 0.03). There was a lower incidence of corticosteroid use in the mirikizumab bio-exposed cohort compared to risankizumab, however, no difference in the bio-naïve cohort. There was no difference in the incidence of therapy change. Zero patients required colectomy. There was a higher proportion of patients with FCP < 200 µg/g (42.8% vs. 16%, p = 0.03) in the mirikizumab cohort. Rates of adverse events were low.
conclusionOur exploratory study in a predominantly bio-exposed cohort suggests mirikizumab use for induction of remission was associated with decreased corticosteroid use and higher FCP response compared to risankizumab in UC.
Indexed as
Identifiers
42171975What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.